Therapeutic composition and delivery system for administering drug

• US 20040062799A1
• Filed: 09/12/2003
• Published: 04/01/2004
• Est. Priority Date: 09/29/1997
• Status: Abandoned Application

• Current Assignee: Atul D. Ayer, Clark P. Allphin, Michael A. Desjardin, Paul M. Hwang
• Original Assignee: Atul D. Ayer, Clark P. Allphin, Michael A. Desjardin, Paul M. Hwang
• Inventors: Hwang, Paul M., Desjardin, Michael A., Ayer, Atul D., Allphin, Clark P.
• Application Number:
  US10/661,168
• Publication Number:
  US 20040062799A1
• Time in Patent Office: Days
• US Class Current: 424/465
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A therapeutic composition comprising a drug and a polyitol, a dosage form comprising the therapeutic composition, and the method of using the therapeutic composition and the dosage form are disclosed for an indicated therapy.

Claims

1. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug orally administrable to a patient and 60 wt % to 99.5 wt % of a polyitol pharmaceutically acceptable carrier for aiding in administering the drug to the patient.

2. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug orally administrable to a patient and 60 wt % to 99.5 wt % of a tetritol compatible with the drug as a pharmaceutically acceptable carrier for aiding in administering the drug to the patient.

3. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug orally administrable to a patient and 60 wt % to 99.5 wt % of a pentitol compatible with the drug as a pharmaceutically acceptable carrier for aiding in administering the drug to the patient.

4. A therapeutic composition comprising 0.5 wt % to 65 wt % of a drug orally administrable to a patient and 60 wt % to 99.5 wt % of a hexitol compatible with the drug as a pharmaceutically acceptable carrier for aiding in administering the drug to the patient.

5. A dosage form for delivering a drug to a patient, wherein the dosage form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient, and 65 wt % to 99.5 wt % of a polyitol compatible with the drug as a pharmaceutically acceptable carrier for the polyitol, for delivering the drug;

a wall that surrounds the drug and the polyitol permeable to fluid and impermeable to the drug and polyitol; and

an exit in the wall for delivering the drug from the dosage form to the patient.

6. A dosage form for delivering a drug to a patient, wherein the dosage form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient and 60 wt % to 99.5 wt % of a tetritol compatible with the drug, as a pharmaceutically carrier for delivering the drug;

a wall that surrounds the drug and tetritol permeable to fluid and impermeable to drug and tetritol, and an exit in the wall for delivering the drug from the dosage from to the patient.

7. A dosage form for delivering a drug to a patient, wherein the dosage form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient and 60 wt % to 99.5 wt % of a pentitol compatible with the drug and serves as a pharmaceutically carrier for drug for delivering the drug;

a wall that surrounds the drug and pentitol permeable to fluid and impermeable to drug and pentitol; and

an exit in the wall for delivering the drug from the dosage from to the patient.

8. A dosage form for delivering a drug to a patient, wherein the dosage form comprises 0.5 wt % to 65 wt % of a drug orally deliverable to a patient, and 60 wt % to 99.5 wt % of a hexitol compatible with the drug and operates as a pharmaceutically carrier for delivering the drug;

a wall that surrounds the drug and hexitol permeable to the passage or fluid and impermeable to drug and the hexitol; and

, an exit in the wall for delivering the drug from the dosage form to the patient.

9. A dosage form for delivering oxybutynin to a patient, wherein the dosage form comprises 0.5 wt % to 65 wt % of oxybutynin orally deliverable to a patient, and 60 wt % to 99.5 wt % of a hexitol compatible with the oxybutynin that performs as a pharmaceutically acceptable carrier for oxybutynin;

a wall that surrounds oxybutynin and hexitol and is permeable to the passage of fluid present in a patient and impermeable to the passage of oxybutynin and hexitol; and

, an exit in the wall for delivering oxybutynin from the dosage from to the patient.

10. The dosage form according to claim 9, wherein the hexitol is mannitol.

11. The dosage form according to claim 9, wherein oxybutynin is present as oxybutynin hydrochloride.